208 related articles for article (PubMed ID: 23143746)
1. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.
Nobuoka D; Yoshikawa T; Takahashi M; Iwama T; Horie K; Shimomura M; Suzuki S; Sakemura N; Nakatsugawa M; Sadamori H; Yagi T; Fujiwara T; Nakatsura T
Cancer Immunol Immunother; 2013 Apr; 62(4):639-52. PubMed ID: 23143746
[TBL] [Abstract][Full Text] [Related]
2. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
3. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
4. Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy.
Nobuoka D; Yoshikawa T; Fujiwara T; Nakatsura T
Hum Vaccin Immunother; 2013 Jun; 9(6):1234-6. PubMed ID: 23411443
[TBL] [Abstract][Full Text] [Related]
5. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
6. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
7. Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients.
Sasada T; Takedatsu H; Azuma K; Koga M; Maeda Y; Shichijo S; Shoumura H; Hirai T; Takabayashi A; Itoh K
Cancer Res; 2004 Apr; 64(8):2882-8. PubMed ID: 15087407
[TBL] [Abstract][Full Text] [Related]
8. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
9. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
[TBL] [Abstract][Full Text] [Related]
10. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.
Iwama T; Horie K; Yoshikawa T; Nobuoka D; Shimomura M; Sawada Y; Nakatsura T
Int J Oncol; 2013 Mar; 42(3):831-8. PubMed ID: 23354275
[TBL] [Abstract][Full Text] [Related]
11. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.
Alves PM; Faure O; Graff-Dubois S; Gross DA; Cornet S; Chouaib S; Miconnet I; Lemonnier FA; Kosmatopoulos K
Cancer Res; 2003 Dec; 63(23):8476-80. PubMed ID: 14679012
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice.
Tang XD; Liang GP; Li C; Wan Y; Chen T; Chen L; Yu ST; Xiong Z; Fang DC; Wang GZ; Yang SM
Cancer Immunol Immunother; 2010 Jul; 59(7):1041-7. PubMed ID: 20182872
[TBL] [Abstract][Full Text] [Related]
13. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
[TBL] [Abstract][Full Text] [Related]
14. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
[TBL] [Abstract][Full Text] [Related]
15. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
[TBL] [Abstract][Full Text] [Related]
16. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
[TBL] [Abstract][Full Text] [Related]
17. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
18. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
20. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]